FDA Approval Is "First Action" For 32% Of NMEs; Rate Less Than Other NDAs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approved approximately one-third of new molecular entities with user fee deadlines in 2002 on the first cycle.